Generic Name


Therapeutic Category


Tranexamic acid

Tranexamic acid 250mg Capsules

Tranexamic acid 500mg Capsules



    TRANCAP 250

    Each capsule contains:

    Tranexamic Acid BP                250mg

    Size '2' hard gelatin capsule having yellow body and green cap.

    TRANCAP 500

    Each capsule contains:

    Tranexamic Acid BP                500mg

    White compacted powder filled in size '0' hard gelatin capsule with blue cap and grey body



    Administration: May be taken with or without food

    Pregnancy :Category B

    Storage: Store below 25°C; Keep out of reach of children.

    Missed dose: Take the missed dose as soon as you remember; Skip the missed dose if it is almost time for your next scheduled dose; Do not take extra medicine to make up the missed dose.


    Pharmacotherapeutic Group: Anti-fibrinolytic agent

     Pharmacodynamic properties:

    Anti-fibrinolytic agent: Tranexamic acid is an antifibrinolytic agent that competitively inhibits the activation of plasminogen to plasmin and prevents the degradation of fibrin clot. At much higher concentrations it is a non-competitive inhibitor of plasmin.

    In melasma: Melasma is tan or dark skin coloration. It is the hyperpigmentation due to overproduction of melanin. Tranexamic acid interferes with tyrosinase enzyme and inhibits melanin synthesis.

     Pharmacokinetic properties:

    Absorption: Absorbed from the GI tract; peak plasma concentrations after 3 hr (oral); Bioavailability: 30-50%, unaffected by food intake.

    Distribution: Widely throughout the body. Protein-binding: Very low. Crosses the placenta, blood brain barrier and distributed into breast milk.

    Excretion: Urine (as unchanged drug); Elimination half-life: 2hr.


    Dermal, epidermal and mixed melasma; Dermal erythema; Vaginal bleeding; Menorrhagia; Dentistry; Hemophilia; Injuries and trauma; Surgery; Nasal bleeding.


    As anti-fibrinolytic agent: 500mg two to three times daily. 

    In melasma: 250mg twice daily for 3 months.


    Severe renal failure, Hypersensitivity, Thromboembolic disease, subarachnoid bleeding, Colour vision disorders, History of convulsion, Disseminated intravascular coagulation; consumption coagulopathy.


    Mild to moderate renal impairment, Irregular menstrual bleeding, Previous history of thromboembolic disease, Haematuria, Oral contraceptives.


    Diarrhoea, nausea, vomiting, disturbances in colour vision, giddiness, thromboembolic events.


    Potentially Fatal: Increased risk of thrombus formation with estrogens, Factor IX complex concentrates or anti-inhibitor coagulant concentrates. Increased risk of fatal thrombotic complications with tretinoin in acute promyelocyticleukaemia.


    TRANCAP 250: Each box contains 10 blister packs of 10 capsules per strip

    TRANCAP 500: Each box contains 10 blister packs of 10 capsules per strip